Ritedose Meets Workforce Demand with RISE Program Partnership with InSpring and Benedict College
COLUMBIA, SC – October. 8, 2024 – To meet a need for demanding company roles, The Ritedose Corporation (Ritedose) partnered with inSpring and Benedict College to develop RISE, a workforce initiative for international STEM students at the Historically Black College and University (HBCU).
Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*
September 17, 2024 -- The Ritedose Corporation, Inc. (Ritedose), the largest CDMO in the United States specializing in sterile Blow Fill Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, is proud to partner with Verona Pharma plc (Nasdaq: VRNA) as the development and manufacturing partner
Ritedose Pharmaceuticals Continues Tradition of Giving Back – Increases its Annual Donation to Unprecedented Amount of 1 Million Doses of Respiratory Medications to Dispensary of Hope for Low-income and Chronically lll Patients
COLUMBIA, S.C., August 12, 2024 – Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), the leading contract development and manufacturing organization (CDMO) specializing in sterile Blow Fill Seal (BFS) production, announces today that it will donate 1 Million (1M) doses to the national charitable medication distributor, Dispensary of Hope,
Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: <em>Sodium Chloride Injection 23.4% (120mEq/30 mL)</em>
COLUMBIA, S.C. (August 11, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Sodium Chloride Injection 23.4% (120mEq/30 mL). It is the 10th of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division
Ritedose Releases Two New Single-Dose Syringe Products for Hospital Pharmacies: <em>Phenylephrine Hydrochloride Injection 0.8 mg/10 mL (80 mcg/mL) and Phenylephrine Hydrochloride Injection 1 mg/10 mL (100 mcg/mL)</em>
COLUMBIA, S.C. (May 21, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, launched two new unit dose syringe products, Phenylephrine Hydrochloride Injection 0.8 mg/10 mL (80 mcg/mL) and Phenylephrine Hydrochloride Injection 1 mg/10 mL (100 mcg/mL). These are part of a six-month, 12-product rollout from Ritedose for
Ritedose Brings New Unit Dose Syringe Product to the Market: <em>Succinylcholine Chloride Injection 100 mg/5 mL (20 mg/mL)</em>
COLUMBIA, S.C. (May 14, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Succinylcholine Chloride Injection 100 mg/5 mL (20 mg/mL). It is part of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a
Ritedose Launches New Single-Dose Syringe Product: <em>Labetalol Hydrochloride Injection 20 mg/4 mL (5mg/mL)</em>
COLUMBIA, S.C. (April 30, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Labetalol Hydrochloride Injection 20 mg/4 mL (5mg/mL). It is part of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division
Ritedose Releases Two New Single-Dose Syringe Products to the Market: <em>Glycopyrrolate Injection 0.6 mg/3 mL (0.2 mg/mL) and Glycopyrrolate Injection 1 mg/5 mL (0.2 mg/mL)</em>
COLUMBIA, S.C. (April 16, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, launched two new unit dose syringe products, Glycopyrrolate Injection 0.6 mg/3 mL (0.2 mg/mL) and Glycopyrrolate Injection 1 mg/5 mL (0.2 mg/mL). These are part of a 12-product rollout expected from Ritedose over the next
Ritedose Launches Two New Single-Dose Syringe Products: <em>Neostigmine Methylsulfate Injection 3 mg/3 mL (1 mg/mL) & Neostigmine Methylsulfate Injection 5 mg/5 mL (1mg/mL)</em>
COLUMBIA, S.C. (April 2, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, launched two new unit dose syringe products, Neostigmine Methylsulfate Injection 3 mg/3 mL (1 mg/mL) and Neostigmine Methylsulfate Injection 5 mg/5 mL (1mg/mL). These are part of a 12-product rollout expected from Ritedose over the
Ritedose Announces Launch of New Unit Dose Syringe Product: <em>Succinylcholine Chloride Injection 200 mg/10 mL (20 mg/mL)</em>
COLUMBIA, S.C. (March 25, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Succinylcholine Chloride Injection 200 mg/10 mL (20 mg/mL). It is the first of 12 Ritedose products expected to hit the market over the next six months for
- 1
- 2
Recent Comments